1
|
Andrikopoulos N, Tang H, Wang Y, Liang X, Li Y, Davis TP, Ke PC. Exploring Peptido-Nanocomposites in the Context of Amyloid Diseases. Angew Chem Int Ed Engl 2024; 63:e202309958. [PMID: 37943171 DOI: 10.1002/anie.202309958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 10/27/2023] [Accepted: 11/09/2023] [Indexed: 11/10/2023]
Abstract
Therapeutic peptides are a major class of pharmaceutical drugs owing to their target-binding specificity as well as their versatility in inhibiting aberrant protein-protein interactions associated with human pathologies. Within the realm of amyloid diseases, the use of peptides and peptidomimetics tailor-designed to overcome amyloidogenesis has been an active research endeavor since the late 90s. In more recent years, incorporating nanoparticles for enhancing the biocirculation and delivery of peptide drugs has emerged as a frontier in nanomedicine, and nanoparticles have further demonstrated a potency against amyloid aggregation and cellular inflammation to rival strategies employing small molecules, peptides, and antibodies. Despite these efforts, however, a fundamental understanding of the chemistry, characteristics and function of peptido-nanocomposites is lacking, and a systematic analysis of such strategy for combating a range of amyloid pathogeneses is missing. Here we review the history, principles and evolving chemistry of constructing peptido-nanocomposites from bottom up and discuss their future application against amyloid diseases that debilitate a significant portion of the global population.
Collapse
Affiliation(s)
- Nicholas Andrikopoulos
- Nanomedicine Center, The Great Bay Area National Institute for Nanotechnology Innovation, 136 Kaiyuan Avenue, Guangzhou, 510700, China
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
| | - Huayuan Tang
- College of Mechanics and Materials, Hohai University, Nanjing, 211100, China
- Department of Physics and Astronomy, Clemson University, Clemson, SC 29634, USA
| | - Yue Wang
- Nanomedicine Center, The Great Bay Area National Institute for Nanotechnology Innovation, 136 Kaiyuan Avenue, Guangzhou, 510700, China
- School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 510006, China
| | - Xiufang Liang
- Nanomedicine Center, The Great Bay Area National Institute for Nanotechnology Innovation, 136 Kaiyuan Avenue, Guangzhou, 510700, China
- School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 510006, China
| | - Yuhuan Li
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
- Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, 200032, China
| | - Thomas P Davis
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Qld 4072, Australia
| | - Pu Chun Ke
- Nanomedicine Center, The Great Bay Area National Institute for Nanotechnology Innovation, 136 Kaiyuan Avenue, Guangzhou, 510700, China
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Qld 4072, Australia
| |
Collapse
|
2
|
Ibáñez-Moragues M, Fernández-Barahona I, Santacruz R, Oteo M, Luján-Rodríguez VM, Muñoz-Hernando M, Magro N, Lagares JI, Romero E, España S, Espinosa-Rodríguez A, García-Díez M, Martínez-Nouvilas V, Sánchez-Tembleque V, Udías JM, Valladolid-Onecha V, Martín-Rey MÁ, Almeida-Cordon EI, Viñals i Onsès S, Pérez JM, Fraile LM, Herranz F, Morcillo MÁ. Zinc-Doped Iron Oxide Nanoparticles as a Proton-Activatable Agent for Dose Range Verification in Proton Therapy. Molecules 2023; 28:6874. [PMID: 37836718 PMCID: PMC10574368 DOI: 10.3390/molecules28196874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 09/13/2023] [Accepted: 09/26/2023] [Indexed: 10/15/2023] Open
Abstract
Proton therapy allows the treatment of specific areas and avoids the surrounding tissues. However, this technique has uncertainties in terms of the distal dose fall-off. A promising approach to studying the proton range is the use of nanoparticles as proton-activatable agents that produce detectable signals. For this, we developed an iron oxide nanoparticle doped with Zn (IONP@Zn-cit) with a hydrodynamic size of 10 nm and stability in serum. Cytotoxicity, defined as half of the surveillance, was 100 μg Zn/mL in the U251 cell line. The effect on clonogenic cell death was tested after X-ray irradiation, which suggested a radioprotective effect of these nanoparticles at low concentrations (1-10 μg Zn/mL). To evaluate the production of positron emitters and prompt-gamma signals, IONP@Zn-cit was irradiated with protons, obtaining prompt-gamma signals at the lowest measured concentration (10 mg Zn/mL). Finally, 67Ga-IONP@Zn-cit showed accumulation in the liver and spleen and an accumulation in the tumor tissue of 0.95% ID/g in a mouse model of U251 cells. These results suggest the possibility of using Zn nanoparticles as proton-activatable agents to verify the range by prompt gamma detection and face the challenges of prompt gamma detection in a specific biological situation, opening different avenues to go forward in this field.
Collapse
Affiliation(s)
- Marta Ibáñez-Moragues
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas CIEMAT, Medical Applications of Ionizing Radiation Unit, 28040 Madrid, Spain; (R.S.); (M.O.); (V.M.L.-R.); (N.M.); (J.I.L.); (E.R.); (J.M.P.)
| | - Irene Fernández-Barahona
- Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, Spain;
- Instituto de Química Médica—Consejo Superior de Investigaciones Científicas IQM-CSIC, Nanomedicine and Molecular Imaging Group, 28006 Madrid, Spain; (M.M.-H.)
| | - Rocío Santacruz
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas CIEMAT, Medical Applications of Ionizing Radiation Unit, 28040 Madrid, Spain; (R.S.); (M.O.); (V.M.L.-R.); (N.M.); (J.I.L.); (E.R.); (J.M.P.)
| | - Marta Oteo
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas CIEMAT, Medical Applications of Ionizing Radiation Unit, 28040 Madrid, Spain; (R.S.); (M.O.); (V.M.L.-R.); (N.M.); (J.I.L.); (E.R.); (J.M.P.)
| | - Víctor M. Luján-Rodríguez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas CIEMAT, Medical Applications of Ionizing Radiation Unit, 28040 Madrid, Spain; (R.S.); (M.O.); (V.M.L.-R.); (N.M.); (J.I.L.); (E.R.); (J.M.P.)
| | - María Muñoz-Hernando
- Instituto de Química Médica—Consejo Superior de Investigaciones Científicas IQM-CSIC, Nanomedicine and Molecular Imaging Group, 28006 Madrid, Spain; (M.M.-H.)
| | - Natalia Magro
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas CIEMAT, Medical Applications of Ionizing Radiation Unit, 28040 Madrid, Spain; (R.S.); (M.O.); (V.M.L.-R.); (N.M.); (J.I.L.); (E.R.); (J.M.P.)
| | - Juan I. Lagares
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas CIEMAT, Medical Applications of Ionizing Radiation Unit, 28040 Madrid, Spain; (R.S.); (M.O.); (V.M.L.-R.); (N.M.); (J.I.L.); (E.R.); (J.M.P.)
| | - Eduardo Romero
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas CIEMAT, Medical Applications of Ionizing Radiation Unit, 28040 Madrid, Spain; (R.S.); (M.O.); (V.M.L.-R.); (N.M.); (J.I.L.); (E.R.); (J.M.P.)
| | - Samuel España
- Nuclear Physics Group, Universidad Complutense de Madrid, IPARCOS &EMFTEL, CEI Moncloa, 28040 Madrid, Spain; (S.E.); (A.E.-R.); (M.G.-D.); (V.M.-N.); (V.S.-T.); (J.M.U.); (V.V.-O.); (L.M.F.)
- Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Ciudad Universitaria, 28040 Madrid, Spain
| | - Andrea Espinosa-Rodríguez
- Nuclear Physics Group, Universidad Complutense de Madrid, IPARCOS &EMFTEL, CEI Moncloa, 28040 Madrid, Spain; (S.E.); (A.E.-R.); (M.G.-D.); (V.M.-N.); (V.S.-T.); (J.M.U.); (V.V.-O.); (L.M.F.)
- Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Ciudad Universitaria, 28040 Madrid, Spain
| | - Miguel García-Díez
- Nuclear Physics Group, Universidad Complutense de Madrid, IPARCOS &EMFTEL, CEI Moncloa, 28040 Madrid, Spain; (S.E.); (A.E.-R.); (M.G.-D.); (V.M.-N.); (V.S.-T.); (J.M.U.); (V.V.-O.); (L.M.F.)
- Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Ciudad Universitaria, 28040 Madrid, Spain
| | - Víctor Martínez-Nouvilas
- Nuclear Physics Group, Universidad Complutense de Madrid, IPARCOS &EMFTEL, CEI Moncloa, 28040 Madrid, Spain; (S.E.); (A.E.-R.); (M.G.-D.); (V.M.-N.); (V.S.-T.); (J.M.U.); (V.V.-O.); (L.M.F.)
- Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Ciudad Universitaria, 28040 Madrid, Spain
| | - Víctor Sánchez-Tembleque
- Nuclear Physics Group, Universidad Complutense de Madrid, IPARCOS &EMFTEL, CEI Moncloa, 28040 Madrid, Spain; (S.E.); (A.E.-R.); (M.G.-D.); (V.M.-N.); (V.S.-T.); (J.M.U.); (V.V.-O.); (L.M.F.)
- Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Ciudad Universitaria, 28040 Madrid, Spain
| | - José Manuel Udías
- Nuclear Physics Group, Universidad Complutense de Madrid, IPARCOS &EMFTEL, CEI Moncloa, 28040 Madrid, Spain; (S.E.); (A.E.-R.); (M.G.-D.); (V.M.-N.); (V.S.-T.); (J.M.U.); (V.V.-O.); (L.M.F.)
- Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Ciudad Universitaria, 28040 Madrid, Spain
| | - Víctor Valladolid-Onecha
- Nuclear Physics Group, Universidad Complutense de Madrid, IPARCOS &EMFTEL, CEI Moncloa, 28040 Madrid, Spain; (S.E.); (A.E.-R.); (M.G.-D.); (V.M.-N.); (V.S.-T.); (J.M.U.); (V.V.-O.); (L.M.F.)
- Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Ciudad Universitaria, 28040 Madrid, Spain
| | - Miguel Á. Martín-Rey
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas CIEMAT, Hematopoietic Innovative Therapies Unit, 28040 Madrid, Spain;
| | - Edilia I. Almeida-Cordon
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas CIEMAT, Animal Facility Unit, 28040 Madrid, Spain;
| | - Sílvia Viñals i Onsès
- Center for Microanalysis of Materials (CMAM), Universidad Autónoma de Madrid, 28049 Madrid, Spain;
| | - José Manuel Pérez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas CIEMAT, Medical Applications of Ionizing Radiation Unit, 28040 Madrid, Spain; (R.S.); (M.O.); (V.M.L.-R.); (N.M.); (J.I.L.); (E.R.); (J.M.P.)
| | - Luis Mario Fraile
- Nuclear Physics Group, Universidad Complutense de Madrid, IPARCOS &EMFTEL, CEI Moncloa, 28040 Madrid, Spain; (S.E.); (A.E.-R.); (M.G.-D.); (V.M.-N.); (V.S.-T.); (J.M.U.); (V.V.-O.); (L.M.F.)
- Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Ciudad Universitaria, 28040 Madrid, Spain
| | - Fernando Herranz
- Instituto de Química Médica—Consejo Superior de Investigaciones Científicas IQM-CSIC, Nanomedicine and Molecular Imaging Group, 28006 Madrid, Spain; (M.M.-H.)
| | - Miguel Ángel Morcillo
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas CIEMAT, Medical Applications of Ionizing Radiation Unit, 28040 Madrid, Spain; (R.S.); (M.O.); (V.M.L.-R.); (N.M.); (J.I.L.); (E.R.); (J.M.P.)
| |
Collapse
|
3
|
Salvanou EA, Kolokithas-Ntoukas A, Liolios C, Xanthopoulos S, Paravatou-Petsotas M, Tsoukalas C, Avgoustakis K, Bouziotis P. Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with 68Ga and 177Lu as Potential Theranostic Agents. NANOMATERIALS 2022; 12:nano12142490. [PMID: 35889715 PMCID: PMC9321329 DOI: 10.3390/nano12142490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Revised: 07/09/2022] [Accepted: 07/15/2022] [Indexed: 12/04/2022]
Abstract
Theranostic radioisotope pairs such as Gallium-68 (68Ga) for Positron Emission Tomography (PET) and Lutetium-177 (177Lu) for radioisotopic therapy, in conjunction with nanoparticles (NPs), are an emerging field in the treatment of cancer. The present work aims to demonstrate the ability of condensed colloidal nanocrystal clusters (co-CNCs) comprised of iron oxide nanoparticles, coated with alginic acid (MA) and stabilized by a layer of polyethylene glycol (MAPEG) to be directly radiolabeled with 68Ga and its therapeutic analog 177Lu. 68Ga/177Lu- MA and MAPEG were investigated for their in vitro stability. The biocompatibility of the non-radiolabeled nanoparticles, as well as the cytotoxicity of MA, MAPEG, and [177Lu]Lu-MAPEG were assessed on 4T1 cells. Finally, the ex vivo biodistribution of the 68Ga-labeled NPs as well as [177Lu]Lu-MAPEG was investigated in normal mice. Radiolabeling with both radioisotopes took place via a simple and direct labelling method without further purification. Hemocompatibility was verified for both NPs, while MTT studies demonstrated the non-cytotoxic profile of the nanocarriers and the dose-dependent toxicity for [177Lu]Lu-MAPEG. The radiolabeled nanoparticles mainly accumulated in RES organs. Based on our preliminary results, we conclude that MAPEG could be further investigated as a theranostic agent for PET diagnosis and therapy of cancer.
Collapse
Affiliation(s)
- Evangelia-Alexandra Salvanou
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece; (E.-A.S.); (C.L.); (S.X.); (M.P.-P.); (C.T.)
- Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Patras, Greece; (A.K.-N.); (K.A.)
| | - Argiris Kolokithas-Ntoukas
- Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Patras, Greece; (A.K.-N.); (K.A.)
| | - Christos Liolios
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece; (E.-A.S.); (C.L.); (S.X.); (M.P.-P.); (C.T.)
- Laboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece
| | - Stavros Xanthopoulos
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece; (E.-A.S.); (C.L.); (S.X.); (M.P.-P.); (C.T.)
| | - Maria Paravatou-Petsotas
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece; (E.-A.S.); (C.L.); (S.X.); (M.P.-P.); (C.T.)
| | - Charalampos Tsoukalas
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece; (E.-A.S.); (C.L.); (S.X.); (M.P.-P.); (C.T.)
| | - Konstantinos Avgoustakis
- Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Patras, Greece; (A.K.-N.); (K.A.)
| | - Penelope Bouziotis
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece; (E.-A.S.); (C.L.); (S.X.); (M.P.-P.); (C.T.)
- Correspondence: ; Tel.: +30-2106503687
| |
Collapse
|
4
|
Synthesis and in vitro proof-of-concept studies on bispecific iron oxide magnetic nanoparticles targeting PSMA and GRP receptors for PET/MR imaging of prostate cancer. Int J Pharm 2022; 624:122008. [PMID: 35820513 DOI: 10.1016/j.ijpharm.2022.122008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2021] [Revised: 06/08/2022] [Accepted: 07/05/2022] [Indexed: 11/20/2022]
Abstract
Prostate cancer (PCa) is the most common malignancy worldwide in men. This is a proof-of-concept study describing the development of 68Ga-magnetic iron oxide nanoparticles (mNP) targeting prostate specific membrane antigen (PSMA) and gastrin releasing peptide (GRPR) receptors as potential tools for diagnosis of PCa with PET/MRI. Two pharmacophores targeting PSMA, 1, and GRPR, 2, were coupled to mNPs carrying -SH (mNP-S1/2) or -NH2 (mNP-N1/2) groups. The mNP-S1/2 and mNP-N1/2 were characterized for their size, zeta potential, structure, and efficiency of functionalization using dynamic light scattering (DLS), FT-IR and RP-HPLC. A direct 68Ga-labelling procedure was followed, where 68Ga-mNP-N1/2 proved superior to 68Ga-mNP-S1/2 regarding radiolabelling efficiency, and thus were further evaluated in vitro. Toxicity studies in PCa cells (LNCaP, PC-3) showed low toxicity, and minimal hemolysis of red blood cells. In vitro assays in cells expressing PSMA (LNCaP), and GRPR (PC-3), showed specific time-dependent binding (40 min to plateau), high avidity (PC-3: Kd = 28.27 nM, LNCaP: Kd = 11.49 nM) and high internalization rates for 68Ga-mNP-N1/2 in both cell lines.
Collapse
|
5
|
Peserico A, Di Berardino C, Russo V, Capacchietti G, Di Giacinto O, Canciello A, Camerano Spelta Rapini C, Barboni B. Nanotechnology-Assisted Cell Tracking. NANOMATERIALS 2022; 12:nano12091414. [PMID: 35564123 PMCID: PMC9103829 DOI: 10.3390/nano12091414] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/27/2022] [Revised: 04/13/2022] [Accepted: 04/14/2022] [Indexed: 02/06/2023]
Abstract
The usefulness of nanoparticles (NPs) in the diagnostic and/or therapeutic sector is derived from their aptitude for navigating intra- and extracellular barriers successfully and to be spatiotemporally targeted. In this context, the optimization of NP delivery platforms is technologically related to the exploitation of the mechanisms involved in the NP–cell interaction. This review provides a detailed overview of the available technologies focusing on cell–NP interaction/detection by describing their applications in the fields of cancer and regenerative medicine. Specifically, a literature survey has been performed to analyze the key nanocarrier-impacting elements, such as NP typology and functionalization, the ability to tune cell interaction mechanisms under in vitro and in vivo conditions by framing, and at the same time, the imaging devices supporting NP delivery assessment, and consideration of their specificity and sensitivity. Although the large amount of literature information on the designs and applications of cell membrane-coated NPs has reached the extent at which it could be considered a mature branch of nanomedicine ready to be translated to the clinic, the technology applied to the biomimetic functionalization strategy of the design of NPs for directing cell labelling and intracellular retention appears less advanced. These approaches, if properly scaled up, will present diverse biomedical applications and make a positive impact on human health.
Collapse
|
6
|
Zheng B, Wu Q, Jiang Y, Hou M, Zhang P, Liu M, Zhang L, Li B, Zhang C. One-pot synthesis of 68Ga-doped ultrasmall gold nanoclusters for PET/CT imaging of tumors. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2021; 128:112291. [PMID: 34474842 DOI: 10.1016/j.msec.2021.112291] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Revised: 06/19/2021] [Accepted: 06/28/2021] [Indexed: 10/20/2022]
Abstract
Gold nanoclusters (AuNCs) have attracted much attention for tumor theranostics in recent years because of their ability of renal clearance and to escape the reticuloendothelial system (RES) sequestration. In this study, we presented a novel method to synthesize 68Ga-doped (labeled) AuNCs by simultaneous reduction of 68GaCl3 and HAuCl4 by glutathione. As synthesized 68Ga-doped, glutathione-coated AuNCs (68Ga-GSH@AuNCs) were ultrasmall in size (<2 nm), highly stable under physiological conditions and renally clearable, and had high efficiency for tumor targeting. To demonstrate the universality of this 68Ga labeling method and further enhance tumor targeting efficiency, arginine-glycine-aspartate (RGD)-containing peptide was introduced as co-reductant to synthesize RGD peptide and glutathione co-coated, 68Ga-labeled AuNCs (68Ga-RGD-GSH@AuNCs). Introduction of RGD peptide did not interfere the synthesis process but significantly enhanced the tumor targeting efficiency of the AuNCs. Our study demonstrated that it was feasible to label AuNCs with gallium-68 by direct reduction of the radioisotope and HAuCl4 with reductant peptides, holding a great potential for clinical translation for PET/CT detection of tumors.
Collapse
Affiliation(s)
- Benchao Zheng
- Department of Nuclear Medicine, Rui Jin Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
| | - Qinghe Wu
- Department of Nuclear Medicine, Rui Jin Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
| | - Yifei Jiang
- Department of Nuclear Medicine, Rui Jin Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
| | - Mengfei Hou
- Department of Nuclear Medicine, Rui Jin Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
| | - Pengli Zhang
- Department of Nuclear Medicine, Rui Jin Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
| | - Meirong Liu
- Department of Nuclear Medicine, Rui Jin Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
| | - Lu Zhang
- Department of Nuclear Medicine, Rui Jin Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
| | - Biao Li
- Department of Nuclear Medicine, Rui Jin Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
| | - Chunfu Zhang
- Department of Nuclear Medicine, Rui Jin Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China.
| |
Collapse
|
7
|
Díez-Villares S, Pellico J, Gómez-Lado N, Grijalvo S, Alijas S, Eritja R, Herranz F, Aguiar P, de la Fuente M. Biodistribution of 68/67Ga-Radiolabeled Sphingolipid Nanoemulsions by PET and SPECT Imaging. Int J Nanomedicine 2021; 16:5923-5935. [PMID: 34475757 PMCID: PMC8405882 DOI: 10.2147/ijn.s316767] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 07/02/2021] [Indexed: 01/15/2023] Open
Abstract
Background and Purpose Non-invasive imaging methodologies, especially nuclear imaging techniques, have undergone an extraordinary development over the last years. Interest in the development of innovative tracers has prompted the emergence of new nanomaterials with a focus on nuclear imaging and therapeutical applications. Among others, organic nanoparticles are of the highest interest due to their translational potential related to their biocompatibility and biodegradability. Our group has developed a promising new type of biocompatible nanomaterials, sphingomyelin nanoemulsions (SNs). The aim of this study is to explore the potential of SNs for nuclear imaging applications. Methods Ready-to-label SNs were prepared by a one-step method using lipid derivative chelators and characterized in terms of their physicochemical properties. Stability was assessed under storage and after incubation with human serum. Chelator-functionalized SNs were radiolabeled with 67Ga and 68Ga, and the radiochemical yield (RCY), radiochemical purity (RCP) and radiochemical stability (RCS) were determined. Finally, the biodistribution of 67/68Ga-SNs was evaluated in vivo and ex vivo. Results Here, we describe a simple and mild one-step method for fast and efficient radiolabeling of SNs with 68Ga and 67Ga radioisotopes. In vivo experiments showed that 67/68Ga-SNs can efficiently and indistinctly be followed up by PET and SPECT. Additionally, we proved that the biodistribution of the 67/68Ga-SNs can be conveniently modulated by modifying the surface properties of different hydrophilic polymers, and therefore the formulation can be further adapted to the specific requirements of different biomedical applications. Conclusion This work supports 67/68Ga-SNs as a novel probe for nuclear imaging with tunable biodistribution and with great potential for the future development of nanotheranostics.
Collapse
Affiliation(s)
- Sandra Díez-Villares
- Nano-Oncology and Translational Therapeutics group, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, Santiago de Compostela, 15706, Spain.,Biomedical Research Networking Center on Oncology (CIBERONC), Madrid, 28029, Spain.,University of Santiago de Compostela (USC), Santiago de Compostela, 15782, Spain
| | - Juan Pellico
- School of Biomedical Engineering & Imaging Sciences, King's College London, St. Thomas' Hospital, London, SE1 7EH, UK.,Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, 28029, Spain
| | - Noemí Gómez-Lado
- Nuclear Medicine Department and Molecular Imaging Group, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, Santiago de Compostela, 15706, Spain
| | - Santiago Grijalvo
- Institute for Advanced Chemistry of Catalonia (IQAC), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, E-08034, Spain.,Biomedical Research Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, 28029, Spain
| | - Sandra Alijas
- Nano-Oncology and Translational Therapeutics group, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, Santiago de Compostela, 15706, Spain
| | - Ramon Eritja
- Institute for Advanced Chemistry of Catalonia (IQAC), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, E-08034, Spain.,Biomedical Research Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, 28029, Spain
| | - Fernando Herranz
- Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, 28029, Spain.,NanoMedMol Group, Instituto de Química Medica (IQM),Consejo Superior de Investigaciones Científicas (CSIC), Madrid, 28006, Spain
| | - Pablo Aguiar
- Nuclear Medicine Department and Molecular Imaging Group, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, Santiago de Compostela, 15706, Spain
| | - María de la Fuente
- Nano-Oncology and Translational Therapeutics group, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, Santiago de Compostela, 15706, Spain.,Biomedical Research Networking Center on Oncology (CIBERONC), Madrid, 28029, Spain
| |
Collapse
|
8
|
Krekorian M, Sandker GGW, Cortenbach KRG, Tagit O, van Riessen NK, Raavé R, Srinivas M, Figdor CG, Heskamp S, Aarntzen EHJG. Characterization of Intrinsically Radiolabeled Poly(lactic- co-glycolic acid) Nanoparticles for ex Vivo Autologous Cell Labeling and in Vivo Tracking. Bioconjug Chem 2021; 32:1802-1811. [PMID: 34161070 PMCID: PMC8377710 DOI: 10.1021/acs.bioconjchem.1c00271] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2021] [Revised: 06/11/2021] [Indexed: 02/04/2023]
Abstract
With the advent of novel immunotherapies, interest in ex vivo autologous cell labeling for in vivo cell tracking has revived. However, current clinically available labeling strategies have several drawbacks, such as release of radiolabel over time and cytotoxicity. Poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) are clinically used biodegradable carriers of contrast agents, with high loading capacity for multimodal imaging agents. Here we show the development of PLGA-based NPs for ex vivo cell labeling and in vivo cell tracking with SPECT. We used primary amine-modified PLGA polymers (PLGA-NH2) to construct NPs similar to unmodified PLGA NPs. PLGA-NH2 NPs were efficiently radiolabeled without chelator and retained the radionuclide for 2 weeks. Monocyte-derived dendritic cells labeled with [111In]In-PLGA-NH2 showed higher specific activity than those labeled with [111In]In-oxine, with no negative effect on cell viability. SPECT/CT imaging showed that radiolabeled THP-1 cells accumulated at the Staphylococcus aureus infection site in mice. In conclusion, PLGA-NH2 NPs are able to retain 111In, independent of chelator presence. Furthermore, [111In]In-PLGA-NH2 allows cell labeling with high specific activity and no loss of activity over prolonged time intervals. Finally, in vivo tracking of ex vivo labeled THP-1 cells was demonstrated in an infection model using SPECT/CT imaging.
Collapse
Affiliation(s)
- Massis Krekorian
- Department
of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands
- Department
of Medical Imaging, Radboud Institute for
Molecular Life Sciences, Radboud university Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands
| | - Gerwin G. W. Sandker
- Department
of Medical Imaging, Radboud Institute for
Molecular Life Sciences, Radboud university Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands
| | - Kimberley R. G. Cortenbach
- Department
of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands
| | - Oya Tagit
- Department
of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands
| | - N. Koen van Riessen
- Department
of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands
- Cenya
Imaging BV, Tweede Kostverlorenkade
11H, 1052 RK Amsterdam, The Netherlands
| | - René Raavé
- Department
of Medical Imaging, Radboud Institute for
Molecular Life Sciences, Radboud university Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands
| | - Mangala Srinivas
- Department
of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands
- Cenya
Imaging BV, Tweede Kostverlorenkade
11H, 1052 RK Amsterdam, The Netherlands
| | - Carl G. Figdor
- Department
of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands
| | - Sandra Heskamp
- Department
of Medical Imaging, Radboud Institute for
Molecular Life Sciences, Radboud university Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands
| | - Erik H. J. G. Aarntzen
- Department
of Medical Imaging, Radboud Institute for
Molecular Life Sciences, Radboud university Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands
| |
Collapse
|
9
|
Ayşe U, Aziz G, Doğangün Y. High-Efficiency Cationic Labeling Algorithm of Macroaggregated Albumin with 68Gallium. Nucl Med Mol Imaging 2021; 55:79-85. [PMID: 33968274 DOI: 10.1007/s13139-021-00687-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 12/11/2020] [Accepted: 01/18/2021] [Indexed: 11/26/2022] Open
Abstract
Purpose The generator product radionuclide gallium-68(68Ga) is widely used for PET/CT imaging agents and the 68Ga-labeled MAA is an attractive alternative to 99mTc-labeled MAA. Using a commercially available MAA labeling kit for 99mTc, we presented a reliable synthesis protocol with a highly efficient, organic solvent-free cationic method in GMP conditions in the Scintomics automated synthesis unit. Methods The labeling process was performed by incubating for 7 min at 90 °C in the borax vial containing the generator product 68GaCl3 MAA-HEPES eluted from the PSH+ cartridge with 1.5 mL 5 molar NaCl. Quality control of the final product content was examined, and radiopharmaceutical production was carried out in accordance with GMP guidelines. Results 68Ga eluted from the generator was obtained in more than 99% radiochemical purity and efficiency. In this case, the labeling efficiency was found to be >99%. When the results of SEM-EDX analysis in the final product were examined, it was determined that most of toxic metals were no appreciable in the product content. Conclusions The radiochemical and chemical purity of the final product allows direct use without purification steps to remove "free 68Ga" or other toxic compounds.
Collapse
Affiliation(s)
- Uğur Ayşe
- Education and Research Hospital, Department of Nuclear Medicine, Pamukkale University, Denizli, Turkey
| | - Gültekin Aziz
- Education and Research Hospital, Department of Nuclear Medicine, Pamukkale University, Denizli, Turkey
| | - Yüksel Doğangün
- Education and Research Hospital, Department of Nuclear Medicine, Pamukkale University, Denizli, Turkey
| |
Collapse
|
10
|
Romero E, Martínez A, Oteo M, Ibañez M, Santos M, Morcillo MÁ. Development and long-term evaluation of a new 68Ge/ 68Ga generator based on nano-SnO 2 for PET imaging. Sci Rep 2020; 10:12756. [PMID: 32728067 PMCID: PMC7392752 DOI: 10.1038/s41598-020-69659-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Accepted: 07/11/2020] [Indexed: 02/07/2023] Open
Abstract
Radionuclide generator systems can routinely provide radionuclides on demand such as 68Ga produced by a 68Ge/68Ga generator without the availability of an on-site accelerator or a research reactor. Thus, in this work nano-SnO2 was used to develop a new 68Ge/68Ga generator which was evaluated over a period of 17 months and 305 elution cycles. The elution yield was 91.1 ± 1.8% in the first 7 mL (1 M HCl as eluent) when the generator was new and then it decreased with time and use to 73.8 ± 1.9%. Around 80% of the elutable 68Ga activity was obtained in 1 mL and the 68Ge content in the eluate did not exceed 1 × 10–4% over the investigation period when it was eluted regularly. The described generator provided adequate results for radiolabelling of DOTA-TOC with direct use of eluate. In addition, [68Ga]Ga-DOTA-TOC was tested satisfactorily for in vivo tumor detection by microPET/CT imaging in a lung cancer mouse model.
Collapse
Affiliation(s)
- Eduardo Romero
- Biomedical Applications and Pharmacokinetics Unit, CIEMAT, 28040, Madrid, Spain
| | - Alfonso Martínez
- Biomedical Applications and Pharmacokinetics Unit, CIEMAT, 28040, Madrid, Spain
| | - Marta Oteo
- Biomedical Applications and Pharmacokinetics Unit, CIEMAT, 28040, Madrid, Spain
| | - Marta Ibañez
- Biomedical Applications and Pharmacokinetics Unit, CIEMAT, 28040, Madrid, Spain
| | | | | |
Collapse
|
11
|
Almasi T, Gholipour N, Akhlaghi M, Mokhtari Kheirabadi A, Mazidi SM, Hosseini SH, Geramifar P, Beiki D, Rostampour N, Shahbazi Gahrouei D. Development of Ga-68 radiolabeled DOTA functionalized and acetylated PAMAM dendrimer-coated iron oxide nanoparticles as PET/MR dual-modal imaging agent. INT J POLYM MATER PO 2020. [DOI: 10.1080/00914037.2020.1785451] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Tinoosh Almasi
- Department of Radiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Nazila Gholipour
- Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
- Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Mehdi Akhlaghi
- Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Seyed Mohammad Mazidi
- Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
| | - Seyed Hassan Hosseini
- Department of Chemical Engineering, University of Science and Technology of Mazandaran, Behshahr, Iran
| | - Parham Geramifar
- Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Davood Beiki
- Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Nima Rostampour
- Department of Radiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | | |
Collapse
|
12
|
Belderbos S, González-Gómez MA, Cleeren F, Wouters J, Piñeiro Y, Deroose CM, Coosemans A, Gsell W, Bormans G, Rivas J, Himmelreich U. Simultaneous in vivo PET/MRI using fluorine-18 labeled Fe 3O 4@Al(OH) 3 nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell distribution. EJNMMI Res 2020; 10:73. [PMID: 32607918 PMCID: PMC7326875 DOI: 10.1186/s13550-020-00655-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Accepted: 06/09/2020] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Mesenchymal stem cells (MSCs) have shown potential for treatment of different diseases. However, their working mechanism is still unknown. To elucidate this, the non-invasive and longitudinal tracking of MSCs would be beneficial. Both iron oxide-based nanoparticles (Fe3O4 NPs) for magnetic resonance imaging (MRI) and radiotracers for positron emission tomography (PET) have shown potential as in vivo cell imaging agents. However, they are limited by their negative contrast and lack of spatial information as well as short half-life, respectively. In this proof-of-principle study, we evaluated the potential of Fe3O4@Al(OH)3 NPs as dual PET/MRI contrast agents, as they allow stable binding of [18F]F- ions to the NPs and thus, NP visualization and quantification with both imaging modalities. RESULTS 18F-labeled Fe3O4@Al(OH)3 NPs (radiolabeled NPs) or mouse MSCs (mMSCs) labeled with these radiolabeled NPs were intravenously injected in healthy C57Bl/6 mice, and their biodistribution was studied using simultaneous PET/MRI acquisition. While liver uptake of radiolabeled NPs was seen with both PET and MRI, mMSCs uptake in the lungs could only be observed with PET. Even some initial loss of fluoride label did not impair NPs/mMSCs visualization. Furthermore, no negative effects on blood cell populations were seen after injection of either the NPs or mMSCs, indicating good biocompatibility. CONCLUSION We present the application of novel 18F-labeled Fe3O4@Al(OH)3 NPs as safe cell tracking agents for simultaneous PET/MRI. Combining both modalities allows fast and easy NP and mMSC localization and quantification using PET at early time points, while MRI provides high-resolution, anatomic background information and long-term NP follow-up, hereby overcoming limitations of the individual imaging modalities.
Collapse
Affiliation(s)
- Sarah Belderbos
- Biomedical MRI, Department of Imaging and Pathology, KU Leuven, 3000, Leuven, Belgium
| | - Manuel Antonio González-Gómez
- NANOMAG Group, Department of Applied Physics, Technological Research Institute, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Frederik Cleeren
- Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000, Leuven, Belgium
| | - Jens Wouters
- Molecular Small Animal Imaging Center (MoSAIC), KU Leuven, 3000, Leuven, Belgium
| | - Yolanda Piñeiro
- NANOMAG Group, Department of Applied Physics, Technological Research Institute, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Christophe M Deroose
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven/UZ Leuven, 3000, Leuven, Belgium
| | - An Coosemans
- Laboratory for Tumor Immunology and Immunotherapy, ImmunOvar Research Group, Department of Oncology, Leuven Cancer Institute, KU Leuven, 3000, Leuven, Belgium.,Department of Gynaecology and Obstetrics, UZ Leuven, 3000, Leuven, Belgium
| | - Willy Gsell
- Biomedical MRI, Department of Imaging and Pathology, KU Leuven, 3000, Leuven, Belgium
| | - Guy Bormans
- Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000, Leuven, Belgium
| | - Jose Rivas
- NANOMAG Group, Department of Applied Physics, Technological Research Institute, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Uwe Himmelreich
- Biomedical MRI, Department of Imaging and Pathology, KU Leuven, 3000, Leuven, Belgium.
| |
Collapse
|
13
|
Kulkarni S, Pandey A, Mutalik S. Liquid metal based theranostic nanoplatforms: Application in cancer therapy, imaging and biosensing. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2020; 26:102175. [DOI: 10.1016/j.nano.2020.102175] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Revised: 02/03/2020] [Accepted: 02/25/2020] [Indexed: 12/29/2022]
|
14
|
Fernández-Barahona I, Muñoz-Hernando M, Herranz F. Microwave-Driven Synthesis of Iron-Oxide Nanoparticles for Molecular Imaging. Molecules 2019; 24:E1224. [PMID: 30925778 PMCID: PMC6479367 DOI: 10.3390/molecules24071224] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 03/21/2019] [Accepted: 03/25/2019] [Indexed: 12/22/2022] Open
Abstract
Here, we present a comprehensive review on the use of microwave chemistry for the synthesis of iron-oxide nanoparticles focused on molecular imaging. We provide a brief introduction on molecular imaging, the applications of iron oxide in biomedicine, and traditional methods for the synthesis of these nanoparticles. The review then focuses on the different examples published where the use of microwaves is key for the production of nanoparticles. We study how the different parameters modulate nanoparticle properties, particularly for imaging applications. Finally, we explore principal applications in imaging of microwave-produced iron-oxide nanoparticles.
Collapse
Affiliation(s)
- Irene Fernández-Barahona
- NanoMedMol Group, Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (CSIC) and CIBERES, C/Juan de la Cierva 3, 28006 Madrid, Spain.
- Facultad de Farmacia, Universidad Complutense de Madrid, Plaza de ramón y Cajal, 28040 Madrid, Spain.
| | - Maria Muñoz-Hernando
- NanoMedMol Group, Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (CSIC) and CIBERES, C/Juan de la Cierva 3, 28006 Madrid, Spain.
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), C/Melchor Fernández-Almagro 3, 28029 Madrid, Spain.
| | - Fernando Herranz
- NanoMedMol Group, Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (CSIC) and CIBERES, C/Juan de la Cierva 3, 28006 Madrid, Spain.
| |
Collapse
|